Aprea Therapeutics, Inc.
APRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001781983
No open-market purchases or sales by Aprea Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $1.90M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Aprea Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 28 | 1 | 22 | −5 |
| Shares | 2.08M | 8.50K | 2.00M | −74.4K (−3.6%) |
| Value | $8.48M | $34.6K | $5.50M | −$2.94M (−34.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Aprea Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 8,504 | $23.4K | 0.00% |
Sold out (6)
Institutions that held Aprea Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Altium Capital Management LP | 137,197 | $558.4K |
| Susquehanna International Group, LLP | 10,119 | $41.2K |
| Royal Bank of Canada | 5,694 | $23.0K |
| The PNC Financial Services Group, Inc. | 1,000 | $4.07K |
| Wells Fargo & Company | 250 | $1.02K |
| Aviso Financial Inc. | 10 | $41 |
Not filed for Q3 2024 yet (1)
Institutions that held Aprea Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 8,504 | $34.6K |